IFNA1 and COVID-19: Our findings are well aligned with other systematic reviews and meta-analysis results which suggest Type 1 interferons reduce mortality and increase faster hospital discharge among patients with COVID-19 [23], IFN-β reduces hospitalization length and respiratory symptoms of COVID-19 [21], and IFN-based agents lead to improvements in chest X-rays findings and lower levels of inflammatory cytokines when used in combination with antivirals, corticosteroids, and traditional medicine for SARS, MERS, and COVID-19 [25].